Behind the fund: How Tampa General’s Innoventures is faring as it closes in on two years after launch


Hospital CEO John Couris talks about what the fund has accomplished since its launch, its future goals and how it's outlasted some of the biggest players in the industry.

Previous Bio-Techne paid CEO Charles Kummeth $15.4 million last year
Next NC pharma startup Genixus gains key partner as it nears first product launch